大脑输液,缩和多巴胺变化 粉样体 阴性 逻辑openic 初级渐进性失语症
Sungwoo Kang1, Seun Jeon2, Young-Gun Lee3
1Department of Neurology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Scientific reports
|March 12, 2025
概括
勒维体病 (LBD) 可能会导致logoopenic变体初级渐进性失言症 (lvPPA),即使阿尔茨海默病 (AD) 不存在. 脑部成像显示了lvPPA患者减少输液和多巴胺载体 (DAT) 吸收的明显模式.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 放射学 放射学是一门学科.
背景情况:
- 逻辑变异性初级渐进性失言症 (lvPPA) 通常与阿尔茨海默氏症 (AD) 相关.
- 勒维体病 (LBD) 是较少见但已报告的lvPPA的原因.
- 了解潜在的病理学对于诊断和治疗至关重要.
研究的目的:
- 为了研究脑输液,缩,多巴胺转运体 (DAT) 吸收和lvPPA患者的语言功能,根据β-粉样蛋白状态进行区分.
- 探索神经成像发现与lvPPA语言缺陷之间的关系.
- 评估LBD对lvPPA表型的潜在贡献.
主要方法:
- 33名lvPPA患者和28名健康对照 (HCs) 接受了MRI,18F-florbetaben PET (粉样蛋白成像) 和DAT PET.
- 患者完成了语言测试,评估了语盲率 (AQ) 和重复率.
- 一般线性模型分析了成像数据和语言分数之间的关联.
主要成果:
- 20名lvPPA患者是粉样蛋白阳性 (lvPPAA+),13名是粉样蛋白阴性 (lvPPAA-).
- 与HC相比,lvPPAA+显示大脑输液普遍减少.
- lvPPAA-在左上边缘和角回旋中表现出减少的输液,两组都在左尾状和黑色物质中减少了DAT吸收.
- 在lvPPAA-中,语言分数与左半球特定区域的输液相关,左上边缘环输液介于左黑质DAT的作用.
结论:
- 虽然阿尔茨海默病是lvPPA的主要原因,但应该考虑LBD,特别是在粉样蛋白阴性病例中.
- 在lvPPA中根据粉样蛋白状况观察到明显的神经成像模式 (输液和DAT吸收).
- 大脑输液和DAT吸收与lvPPA中的语言功能有关,这表明LBD在logoopenic表型中的作用.
相关概念视频
Alzheimer's Disease: Overview
412
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
412
Parkinson's Disease: Overview
415
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
415
Alzheimer's Disease: Treatment
142
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
142


